NEXEON MEDSYSTEMS INC Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 29 rows, 29 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2018-06-30: Reporting owner NEITZEL MICHAEL; Form 4; Security OPTIONS; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2018-06-30: Reporting owner GEORGE KENT J.; Form 4; Security OPTIONS; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2018-04-25: Reporting owner Dittmer Robert Wesley II; Form 3; Security Options; Transaction Holding.
- 2018-03-31: Reporting owner NEITZEL MICHAEL; Form 4; Security OPTIONS; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2018-06-30 | NEITZEL MICHAEL Director | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +893 893 owned after | $20.00 | 2018-07-03 | |
| 2018-06-30 | GEORGE KENT J. Director | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +893 893 owned after | $20.00 | 2018-07-03 | |
| 2018-04-25 holding as of filing | Dittmer Robert Wesley II Director | 3 | Options Derivative · Direct | Holding | no price filed | 2018-04-25 | ||
| 2018-03-31 | NEITZEL MICHAEL Director | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,500 12,500 owned after | $0.87 exercise price | 2018-05-02 | |
| 2018-03-31 | GEORGE KENT J. Director | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,500 12,500 owned after | $0.87 exercise price | 2018-05-01 | |
| 2018-02-28 | Rosellini William Director, Officer (Chief Executive Officer) | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +250,000 250,000 owned after | $0.76 exercise price | 2018-05-01 | |
| 2018-02-28 | Rosellini William Director, Officer (Chief Executive Officer) | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +900,000 900,000 owned after | $0.76 exercise price | 2018-05-01 | |
| 2018-02-28 | MILLER CHRISTOPHER R. Officer (Chief Financial Officer) | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $0.76 exercise price | 2018-05-01 | |
| 2018-02-28 | BLISCHAK BRIAN Officer (President / CCO) | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +57,000 57,000 owned after | $0.76 exercise price | 2018-05-01 | |
| 2018-02-28 | POWELL DANIEL P. Officer (V.P., Sales and Marketing) | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,000 11,000 owned after | $0.76 exercise price | 2018-05-01 | |
| 2017-12-31 | NEITZEL MICHAEL Director | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,500 12,500 owned after | $1.80 exercise price | 2018-05-02 | |
| 2017-12-31 | GEORGE KENT J. Director | 4 | OPTIONS Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,500 12,500 owned after | $1.80 exercise price | 2018-05-01 | |
| 2017-10-10 holding as of filing | NEITZEL MICHAEL Director | 4 | OPTIONS Derivative · Direct | Holding | 12,500 owned after | $1.00 exercise price | 2017-10-10 | |
| 2017-10-03 holding as of filing | MILLER CHRISTOPHER R. Officer (Chief Financial Officer) | 4 | OPTIONS Derivative · Direct | Holding | 306,000 owned after | $1.00 exercise price | 2017-10-03 | |
| 2017-10-01 | NEITZEL MICHAEL Director | 4 | OPTIONS Derivative · Direct | J Other acquisition or disposition (describe transaction) | +12,500 37,500 owned after | $1.00 exercise price | 2017-10-10 | |
| 2017-10-01 | GEORGE KENT J. Director | 4 | Options Derivative · Direct | J Other acquisition or disposition (describe transaction) | +12,500 37,500 owned after | $1.00 exercise price | 2017-10-05 | |
| 2017-07-10 holding as of filing | POWELL DANIEL P. Officer (VP, SALES & MARKETING) | 3 | OPTIONS Derivative · Direct | Holding | $1.25 exercise price | 2017-07-10 | ||
| 2017-07-01 | NEITZEL MICHAEL Director | 4 | OPTIONS Derivative · Direct | J Other acquisition or disposition (describe transaction) | +12,500 25,000 owned after | $1.00 exercise price | 2017-10-10 | |
| 2017-07-01 | GEORGE KENT J. Director | 4 | Options Derivative · Direct | J Other acquisition or disposition (describe transaction) | +12,500 25,000 owned after | $1.00 exercise price | 2017-10-05 | |
| 2017-03-22 holding as of filing | NEITZEL MICHAEL Director | 3 | OPTIONS Derivative · Direct · (m) | Holding | $1.00 exercise price | 2017-03-22 | ||
| 2017-03-13 holding as of filing | GEORGE KENT J. Director | 3 | OPTIONS Derivative · Direct · (m) | Holding | $1.00 exercise price | 2017-03-13 | ||
| 2016-12-31 | ROSELLINI ELIZABETH Other (Shareholder of less than 5%) | 4 | Options Derivative · Direct | J Other acquisition or disposition (describe transaction) | −252,000 0 owned after | $1.00 exercise price | 2017-10-04 | |
| 2016-12-29 holding as of filing | BLISCHAK BRIAN Officer (Pres./Chief Commercial Officer) | 3 | Stock Options Derivative · Direct | Holding | $1.00 exercise price | 2016-12-29 | ||
| 2016-12-21 | MILLER CHRISTOPHER R. Officer (Chief Financial Officer) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +306,000 306,000 owned after | $1.00 exercise price | 2016-12-29 | |
| 2016-09-26 holding as of filing | BATES MARK C. Director, Officer (CHIEF INNOVATION OFFICER) | 3/A | OPTIONS TO PURCHASE COMMON STOCK Derivative · Direct | Holding | $1.00 exercise price | 2016-09-26 | ||
| 2016-09-08 holding as of filing | BATES MARK C. Director, Officer (CHIEF INNOVATION OFFICER) | 3 | OPTIONS TO PURCHASE COMMON STOCK Derivative · Direct | Holding | $1.00 exercise price | 2016-09-08 | ||
| 2016-09-06 holding as of filing | ROSELLINI ELIZABETH Officer (VP CLINICAL AFFAIRS) | 3 | OPTIONS TO PURCHASE COMMON STOCK Derivative · Direct | Holding | $1.00 exercise price | 2016-09-06 | ||
| 2016-09-06 holding as of filing | ROSELLINI SCIENTIFIC LLC 10% Owner | 3 | OPTIONS TO PURCHASE COMMON STOCK Derivative · Direct | Holding | $1.00 exercise price | 2016-09-06 | ||
| 2016-09-06 holding as of filing | Rosellini William Director, Officer (CHIEF EXECUTIVE OFFICER), 10% Owner | 3 | OPTIONS TO PURCHASE COMMON STOCK Derivative · Indirect · Options held by Rosellini Sccientific LLC | Holding | $1.00 exercise price | 2016-09-06 |